Biogen MA Inc. 225 Binney Street Cambridge, MA 02142 United States PROTOCOL NUMBER: 251PP301 / NCT03068468 Biogen Idec Research
Medscape Neurology - After disappointing trial results, Biogen will discontinue development of gosuranemab for PSP and other primary tauopathies. http://ms.spr.ly/6182Tn3Cq | Facebook
☑️Biogen México — Supplier from Mexico, experience with UNOPS — Health, Laboratory & Measurement, Research, Science & Innovation sectors — DevelopmentAid
Biogen Study - CurePSP
Biogen on Twitter: "Progressive Supranuclear Palsy (#PSP) Awareness Month may be over, but the work doesn't end here. #PSPAwareness https://t.co/oC0MNF0IVD" / Twitter
Biogen on Twitter: "#DYK progressive supranuclear palsy (#PSP) wasn't discovered until 1963 due to its resemblance to Parkinson's disease? #PSPAwarenessMonth https://t.co/59rxSezyHe" / Twitter
Biogen abandons tau antibody for Alzheimer's after phase 2 miss | pharmaphorum
Corio PSP™ – Detox RejuveNation
FAQ on FDA Approval of Aducanumab - CurePSP
Cure PSP - Can Progressive Supranuclear Palsy (PSP) be treated at all? The PASSPORT trial is investigating whether a new investigational study drug may slow the progression of PSP. Biogen plan to
Biogen Reports Top-Line Results from Phase 2 Study in Progressive Supranuclear Palsy | Biogen
PSP — Coleen Heaver
Carla Erba - Latam PSP Lead - Biogen | LinkedIn
PSPH (Human) Recombinant Protein (Q01) - BIOGEN Científica
Acompañamos a... - Pharmexx Argentina part of Ashfield Group | Facebook
Biogen MA Inc. 225 Binney Street Cambridge, MA 02142 United States PROTOCOL NUMBER: 251PP301 / NCT03068468 Biogen Idec Research
These Clinical Study Results are provided for informational purposes only. The study listed may include approved and non
Amanda Pereira Silva - Patient Services Analyst Pl - Biogen | LinkedIn
admin – Page 2 – PSP Society of Canada
Biogen chalks up another failure, but investors' eyes remain firmly on Alzheimer's | Fierce Biotech
After Recent Tau Failure, Biogen Licenses Tau Therapeutic from Ionis for Alzheimer's Disease | BioSpace
Biogen Ends Trial of Its Drug for PSP - CurePSP
What's in Biogen's Clinical Pipeline?
Carla Erba - Latam PSP Lead - Biogen | LinkedIn
Biogen on Twitter: "Chris Henderson, VP, Neuromuscular and Movement Disorders Research Unit, highlights the importance of an early Progressive Supranuclear Palsy (PSP) diagnosis #PSPAwareness https://t.co/xDnZaZYYhT" / Twitter
